HQY vs. ACHC, ENSG, BPMC, EXEL, STVN, ITCI, RVMD, JAZZ, MASI, and CYTK
Should you be buying HealthEquity stock or one of its competitors? The main competitors of HealthEquity include Acadia Healthcare (ACHC), The Ensign Group (ENSG), Blueprint Medicines (BPMC), Exelixis (EXEL), Stevanato Group (STVN), Intra-Cellular Therapies (ITCI), Revolution Medicines (RVMD), Jazz Pharmaceuticals (JAZZ), Masimo (MASI), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
Acadia Healthcare (NASDAQ:ACHC) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
HealthEquity has lower revenue, but higher earnings than Acadia Healthcare. Acadia Healthcare is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
Acadia Healthcare received 45 more outperform votes than HealthEquity when rated by MarketBeat users. However, 69.24% of users gave HealthEquity an outperform vote while only 66.75% of users gave Acadia Healthcare an outperform vote.
Acadia Healthcare currently has a consensus target price of $87.56, indicating a potential upside of 31.96%. HealthEquity has a consensus target price of $96.17, indicating a potential upside of 21.41%. Given HealthEquity's higher possible upside, research analysts plainly believe Acadia Healthcare is more favorable than HealthEquity.
In the previous week, Acadia Healthcare had 6 more articles in the media than HealthEquity. MarketBeat recorded 17 mentions for Acadia Healthcare and 11 mentions for HealthEquity. Acadia Healthcare's average media sentiment score of 1.15 beat HealthEquity's score of 0.22 indicating that HealthEquity is being referred to more favorably in the news media.
Acadia Healthcare has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
HealthEquity has a net margin of 5.57% compared to HealthEquity's net margin of -0.38%. HealthEquity's return on equity of 11.49% beat Acadia Healthcare's return on equity.
99.6% of HealthEquity shares are held by institutional investors. 2.0% of Acadia Healthcare shares are held by company insiders. Comparatively, 2.7% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
HealthEquity beats Acadia Healthcare on 11 of the 18 factors compared between the two stocks.
Get HealthEquity News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HealthEquity Competitors List
Related Companies and Tools
